CAS NO: | 1257792-41-8 |
规格: | ≥98% |
包装 | 价格(元) |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
Hetrombopag (SHR8735; Herombopag; Hengqu) is a novel, potent, orally bioavailable, and non-peptide thrombopoietin (TPO) receptor agonist developed by Jiangsu Hengrui Pharmaceutical for the treatment of thrombocytopenia and aplastic anaemia. In June 2021, hetrombopag gained the first approval in China as a second-line treatment for primary immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA) in adults. Hetrombopag can be used to treat low platelet levels in people who have a certain blood disorder called chronic immune thrombocytopenia purpura or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder.
纯度:≥98%
CAS:1257792-41-8